Eligibility is more than a single weight number
The question “Who can take Mounjaro or Wegovy?” cannot be answered by a brand name and a scale reading. Weight-management injections are prescription medicines. A decision begins by confirming obesity, or overweight linked to a health problem, and then reviewing age, medical history, current medicines, pregnancy or pregnancy plans, and the contraindications for the specific product. The World Health Organization generally defines adult obesity as a body mass index (BMI) of 30 or above, while also explaining that BMI is a surrogate measure of body fat and may need to be read with other measurements and health information [4, 9, 11].
For adults, the commonly used screening point for weight-management medicine is a BMI of 30 or above, or a BMI of 27 or above with a weight-related condition such as high blood pressure or type 2 diabetes. NIDDK states these thresholds, and the registered weight trials in the Wegovy and Zepbound labels studied the same core groups: obesity at a BMI of 30 or above, or overweight from 27 to below 30 with at least one related condition [1, 2, 4]. This opens an assessment; it is not an automatic prescription. A person with a BMI of 31 does not have to start an injection, while a person with a BMI of 28 and a related condition may reasonably enter a structured discussion without medicine being the only option.
Approval and health-service rules also differ by country and product. UK NICE guidance, for example, applies different access criteria for particular medicines and services, and uses lower BMI thresholds for some ethnic groups, including people of Middle Eastern family background, because metabolic risk may appear at a lower BMI. A number taken from an advert or another person’s experience is therefore not a universal decision rule. The clinician needs to check the locally approved label, the intended use and the full health picture [8, 9, 12].
The active ingredient may match, but the approved use may not
Much of the confusion comes from treating Mounjaro and Zepbound as if their approved uses were identical. In the United States both contain tirzepatide, but the current Mounjaro label is for improving glucose control, alongside diet and exercise, in adults and children aged 10 and older with type 2 diabetes. The current Zepbound label, by contrast, covers long-term weight management in adults with obesity, or overweight with a related condition, and states that its safety and effectiveness have not been established in pediatric patients [2, 3]. Sharing an active ingredient does not automatically turn a diabetes indication into a pediatric weight-management indication.
The same principle matters with semaglutide. Wegovy injection has an approved weight-management use, while other semaglutide names and formulations may have different indications. The current Wegovy label also distinguishes injection from tablets: the adolescent weight-management indication from age 12 applies to Wegovy injection, while the safety and effectiveness of Wegovy tablets have not been established in pediatric patients. The product name and formulation must be identified precisely, rather than relying on the phrase “the same ingredient” [1].
In practice, an eligibility question must specify the product, ingredient, purpose and age. The statement “tirzepatide can be used from age 10” is misleading on its own: that age now appears in the Mounjaro label for type 2 diabetes, not in the Zepbound weight-management label. Likewise, “Wegovy can be used from age 12” needs its full context: it refers to Wegovy injection for an adolescent with obesity according to age- and sex-appropriate measurement, under assessment and follow-up, not to any teenager wishing to lose a few kilograms [1, 2, 3, 5].
Wegovy for adolescents: age alone is not enough
Adult BMI tables should not be applied directly to adolescents. Growth changes the relationship between height and weight, so NIDDK explains BMI as a percentile for age and sex. From ages 2 through 19, obesity begins at the 95th percentile or above. The current Wegovy injection label establishes weight-management use from age 12 in adolescents with obesity, and the label’s supporting trial enrolled adolescents whose BMI was at or above the 95th percentile for age and sex [1, 5]. The adult numbers of 27 and 30 should not be transferred to a teenager as though the rule were identical.
FDA documented the expansion of Wegovy injection to adolescents aged 12 and older, and NIDDK advises families of an adolescent aged 12 or older with obesity to discuss weight-management medicines as an additional option with a health professional, not as a replacement for healthy eating and activity. “May be offered” matters: meeting the age and percentile criteria permits an assessment, but it does not settle whether Wegovy suits an individual [6, 7].
A calm assessment includes the growth trajectory, related conditions, current medicines, eating pattern, sleep, mental health and signs of an eating disorder. It also needs a responsible adult and a team able to monitor nutrition, growth, symptoms and adherence. The aim is not to pressure a teenager toward a particular appearance or use an injection because of a comment or an approaching event. Below age 12, the Wegovy label says safety and effectiveness of the injection for weight management are not established; the Zepbound label says safety and effectiveness are not established in any pediatric patient [1, 2, 6].
Formal contraindications: what truly rules treatment out?
The Wegovy and Zepbound labels list two formal contraindications rather than an open-ended list. The first is a personal or family history of medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN 2). The second is a known serious hypersensitivity to the active ingredient or any component of the product; serious reactions may include anaphylaxis or angioedema [1, 2]. If either applies, that specific product is contraindicated under the label. It is not something to test and watch at home.
This is different from common hypothyroidism, an ordinary thyroid nodule, or a history of another thyroid cancer type. The label warning is specific to MTC and MEN 2. It should not be expanded without evidence to every thyroid condition, but it should not be minimized when the family history is unclear. Useful questions are: what exactly was the thyroid diagnosis, was it MTC, and was MEN 2 involved? If information is missing, the clinician may need old records or specialist input before making a decision [1, 2].
Both labels explain that thyroid C-cell tumors occurred in rodents and that the relevance to humans has not been determined. That is the formal warning: it does not mean every user will develop cancer, and it does not permit the contraindication to be ignored. The labels also say routine calcitonin testing or thyroid ultrasound has uncertain value for early detection in this setting. A random panel of tests should not replace a precise medical and family history [1, 2].
Conditions needing careful review are not all absolute bans
There is a difference between a contraindication in the formal contraindications section and a warning or a condition in which a medicine is not recommended. Zepbound, for example, is not recommended in severe gastroparesis, while Wegovy carries a warning about severe gastrointestinal reactions. Both labels also require attention to pancreatitis, gallbladder disease, dehydration and kidney injury, hypersensitivity, and hypoglycemia with certain diabetes medicines. A past condition in this group does not automatically mean approval or refusal; the details, severity and accompanying medicines shape the decision [1, 2].
If you have diabetes and use insulin or a sulfonylurea, the risk of low blood glucose may increase with treatment, so a clinician-led plan and appropriate monitoring are needed. Diabetic retinopathy, severe digestive symptoms, recurrent vomiting, gallbladder disease or a history of pancreatitis should be disclosed before selection. The anesthesia team also needs to know before surgery or an endoscopic procedure using general anesthesia or deep sedation because the labels include a warning about pulmonary aspiration during procedures [1, 2]. This is not advice to alter any dose yourself; it is a reason to make the decision after a real review.
All medicines and supplements matter in the assessment. These products delay gastric emptying and may affect the handling of some oral medicines. Tirzepatide can also reduce the effectiveness of oral hormonal contraception after initiation and after each dose increase; the Zepbound label advises a non-oral method or an additional barrier method for four weeks during those periods. This is a point for the clinician and the person concerned to review, not a rule for selecting a drug online [1, 2, 12].
Pregnancy, older age and unknown products need separate decisions
Weight-loss medicines are not used for the purpose of losing weight during pregnancy. The Wegovy and Zepbound labels state that weight loss offers no benefit during pregnancy and may cause fetal harm, and that treatment should be discontinued when pregnancy is recognized under clinical direction. The Wegovy label specifies discontinuation at least two months before a planned pregnancy because semaglutide remains in the body for a long time. If pregnancy occurs or is planned soon, prompt contact with the prescriber is appropriate rather than an independent decision or waiting for a routine visit. The linked articles on weight medicine in pregnancy and before pregnancy cover the details [1, 2, 4].
The adult labels do not set a simple upper age limit. Wegovy and Zepbound trials included some people aged 65 and older, but fewer people at the oldest ages, which makes individual assessment important. A clinician considers frailty, muscle mass, food intake, kidney health, multiple medicines, dehydration and fall risk when balancing benefit and harm. Age alone is neither automatic approval nor automatic refusal [1, 2].
Finally, medical eligibility for an approved medicine does not make every pen or vial labeled semaglutide or tirzepatide safe. FDA explains that unapproved versions do not undergo the same review for safety, effectiveness and quality, and warns about products sold as “for research purposes” or through unreliable sources. Before asking “Am I eligible?”, the product, source and concentration must be known, and it should come through a licensed prescriber and pharmacy. Do not use an unknown or unlabelled product merely because it carries a familiar ingredient name [10].
How do you know if you are eligible? Assessment is the deciding step
Before the visit, prepare your current height and weight, the weight trend over recent months, and a list of all medicines and supplements. Include diagnoses such as diabetes, high blood pressure, sleep apnea, abnormal lipids or cardiovascular disease. Mention gastrointestinal surgery, symptoms of slow stomach emptying, gallbladder or pancreatic disease, kidney problems, diabetic retinopathy and drug allergies. Ask relatives specifically about MTC or MEN 2 rather than asking generally about “thyroid disease.” This structured review is more useful than requesting a product name in advance [1, 2, 4, 9].
The clinician will calculate adult BMI, or an age- and sex-specific percentile for an adolescent, but will also review waist size, blood pressure, related conditions, food, activity, sleep and previous attempts. NICE emphasizes that starting medicine follows discussion and that medicine should be accompanied by dietary, physical-activity and behavioral support. If a numerical threshold is met but a contraindication exists, the product is not suitable. If there is no contraindication but expected benefit is limited or another route fits better, meeting a BMI threshold does not compel injection treatment [8, 9, 12].
For an individual assessment, the medical team at La Rose can review the picture at the Maadi and Fifth Settlement, New Cairo branches. A visit does not guarantee an injection prescription; its purpose is to clarify eligibility, missing information, and whether medicine or another path is appropriate. Book a consultation and bring reports and a medicine list. Do not start, stop or alter treatment on your own [4, 8].
